Obecabtagene autoleucel is chimeric antigen receptor T-cell therapy under evaluation for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
The FDA has accepted a biologics license application (BLA) from Autolus Therapeutics for the chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel (obe-cel) to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The FDA assigned the BLA with a Prescription Drug User Fee Act (PDUFA) date of November 16, 2024.1
“Acceptance of the BLA filing is an important milestone for Autolus and we look forward to continuing our collaboration with the FDA during the review cycle,” said Christian Itin, PhD, CEO of Autolus Therapeutics, plc, in a news release.1 “With the PDUFA date set for November, we remain focused on preparing for the potential launch of obe-cel.”
The application is supported by data from the Phase II FELIX trial (NCT04404660), in which the drug produced a complete response (CR) rate of 54.3% and a CR with incomplete count recovery (CRi) rate of 21.3% (n = 94).2 The CAR T-cell therapy produced an overall remission rate of 76% (95% CI, 66%-84%; P < .0001).
Investigators enrolled adults with relapsed or refractory adult B-ALL who had at least 5% bone marrow blasts at screening in cohort A, MRD positivity at screening in cohort B, and isolated extramedullary disease at screening in cohort C.2,3 The trial’s primary endpoint was CR/CRi rate by central assessment, with secondary endpoints that included duration of response (DOR), event-free survival (EFS), overall survival, MRD negativity rate, and safety.
As of the data cutoff date of September 13, 2023, 153 patients were enrolled and 127 patients received infusion with obe-cel. Among these patients, 107 were assigned to cohort A, 13 were assigned to cohort B, and 7 were assigned to cohort C. A total of 26 patients discontinued treatment because of death (n = 15), issues related to manufacturing (n = 7), toxicity (n = 2), physician decision (n = 1), and disease progression (n = 1).
Data presented at the 2023 American Society of Hematology Annual Meeting indicated that obe-cel produced high CR/CRi rates across all patients subgroups.3 At a median follow-up of 16.6 months (range, 3.7-36.6), median EFS was 11.7 months (95% CI, 7.2-not evaluable [NE]) among patients administered treatment, the six-month EFS rate was 65% (95% CI, 56%-73%), and the 12-month EFS rate was 50% (95% CI, 39%-59%). Further, 17% of patients who responded to treatment went on to transplant while in remission.
In terms of safety, investigators reported low rates of grade 3 or higher CRS and/or ICANS. Among all patients, 69% experienced grade 1 or 2 CRS and 2% experienced CRS of grade 3 or higher.
Common treatment-emergent adverse effects experienced by 20% or more of patients administered obe-cel included pyrexia (any grade, 29%; grade ≥3, 2%), nausea (26%; 2%), diarrhea (25%; 2%), febrile neutropenia (24%; 24%), anemia (24%; 21%), headache (24%; 0%), neutropenia (23%; 21%), hypotension (22%; 5%), hypokalemia (21%; 6%), and decreased neutrophil count (20%; 20%).
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.